Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the long-term cardiovascular risks associated with polycystic ovary syndrome and highlights the greater effectiveness of lifestyle changes compared to metformin in preventing type 2 diabetes, but provides no new clinical outcomes.

This review discusses the management of long-term risks in women with polycystic ovary syndrome, recommending lifestyle changes to improve insulin sensitivity over relying solely on metformin, and reports no new clinical results.

This article discusses the role of insulin resistance in cardiovascular risk and suggests that lifestyle changes may be more beneficial than metformin in managing polycystic ovary syndrome; it reports no new clinical results.

This abstract reviews the management of polycystic ovary syndrome and highlights the potential benefits of lifestyle changes over metformin in reducing type 2 diabetes risk, yet reports no new clinical outcomes.

This review discusses the lack of long-term clinical studies on metformin's cardiovascular benefits in women with polycystic ovary syndrome, highlighting lifestyle changes as a crucial management strategy for reducing associated risks.

The article concludes that hair loss has many causes and treatments, with medication options like finasteride and minoxidil for men, and minoxidil, hormones, or iron for women, while warning against unproven remedies.

Taking calcium may help elderly with osteoporosis, birth control with levonorgestrel doesn't increase heart attack risk, Salmonella can cause arthritis, a national ethics committee is recommended, and sulfasalazine might help with a hair loss condition.

The document suggests improvements for a hair and scalp disease book and recommends a two-volume skin surgery reference for dermatologists.

This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.

This review discusses the evolution of diagnostic criteria for polycystic ovary syndrome and emphasizes its association with various metabolic and cardiovascular risks, but it provides no new research findings.

This consensus report reviews current knowledge and identifies knowledge gaps concerning the various health aspects of polycystic ovary syndrome, without presenting new clinical findings.

This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.

This review emphasizes the need for comprehensive guidelines to address the cardiometabolic and psychological features of polycystic ovary syndrome, alongside its reproductive aspects, and reports no new results.

This review discusses the current understanding of polycystic ovary syndrome, focusing on its epidemiology, pathophysiology, diagnosis, management, and future research directions, but reports no new clinical results.

This study observed that among a cohort of reproductive-aged women in the U.S., the prevalence of PCOS was about 4.0%, with no significant racial differences between White and Black women.

This study found that testosterone therapy improved physical performance and strength in older men with low testosterone over 36 months, whether administered alone or with finasteride.

This study found that the prevalence of polycystic ovary syndrome was 6.5% in a minimally biased sample of Caucasian women from Spain.

This paper reviews the diagnostic criteria, etiological factors, and treatment approaches for PCOS, highlighting the importance of considering metabolic issues such as insulin resistance and obesity, but reports no new findings.

This study found that testosterone therapy increased bone mineral density in older men with low testosterone, and combining it with finasteride may reduce prostate enlargement associated with testosterone treatment.

This study estimates the total cost of evaluating and treating polycystic ovary syndrome in reproductive-aged women in the United States to be $4.36 billion, suggesting more liberal screening could be beneficial.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.

This review discusses the epidemiology, causes, diagnosis, and management of hirsutism in women, noting that effective treatment requires addressing the root cause as well as the hair growth.

This study found that the prevalence of PCOS in a population of unselected U.S. women was 4.0%, with no significant racial differences between White and Black women.

This review examines the best available evidence for diagnosing and managing PCOS but reports no new clinical results.

This review discusses the various evidence-based and potential applications of metformin in treating and preventing symptoms and complications associated with polycystic ovary syndrome but reports no new clinical results.

This review covers the potential of SVF and ADSC therapies in regenerative medicine and highlights the challenges of regulation and efficacy, without reporting new clinical results.

This study found a 6.5% prevalence of polycystic ovary syndrome among a population of Caucasian women in Spain, based on specific endocrine criteria.

This review examines various methods for assessing hair growth in women, highlighting the usefulness of the mFG visual scoring method for diagnosing hirsutism despite its limitations.

This study estimates the global ginseng market at $2.084 billion, with Korea as the largest distributor, reflecting a trend of growing interest in alternative medicine and health foods.